NADH

Limited but interesting evidence for chronic fatigue syndrome. Oral bioavailability is questionable, and most energy claims exceed the evidence base.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

A small crossover RCT found NADH (10 mg) improved symptoms in 31% of CFS patients vs. 8% placebo. It serves as a direct electron donor in Complex I of the electron transport chain. Oral stability and bioavailability are concerns that enteric-coated formulations attempt to address.

• Direct electron donor in mitochondrial energy production
• May improve symptoms in chronic fatigue syndrome
• Supports dopamine and ATP synthesis

Typical doses: 5-20 mg daily on an empty stomach. Enteric-coated formulations recommended. Usually taken in the morning.

• Generally well-tolerated
• Mild GI discomfort
• Overstimulation or anxiety in sensitive individuals

Unstable in acidic environments; requires enteric coating. Limited safety data for long-term high-dose use.

The landmark CFS study was small. Oral NADH bioavailability is problematic. Whether oral NADH meaningfully increases cellular NADH levels is debated. NAD+ precursors (NMN, NR) may be more practical.

• Energy32
• Focus25
• Recovery22